Good afternoon. We will begin the MacroGenics fourth quarter and full-year 2024 corporate progress and financial results conference call in just a moment. All participants are in a listen-only mode.

MacroGenics has made the final decision to abandon work on one of its more advanced antibody-drug conjugates after taking a look at the latest phase 2 data. The biotech had already paused work on ...

Shares of MacroGenics stock opened at $2.00 on Friday. The company has a market cap of $125.53 million, a PE ratio of -1.27 and a beta of 2.12. MacroGenics has a 52 week low of $1.89 and a 52 week ...

MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The firm had revenue of $49.40 million for the quarter, compared to analyst estimates of $34.17 million.

MacroGenics (MGNX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.75 per share a year ago. These figures are ...

Good afternoon. We will begin the MacroGenics fourth quarter and full year 2024 corporate progress and financial results conference call in just a moment. All participants are in a listen-only ...

MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for cancer treatment, has recently undergone significant ...

H.C. Wainwright lowered the firm’s price target on MacroGenics (MGNX) to $2 from $4 and keeps a Neutral rating on the shares. The firm says it has been a long time coming for discontinuing ...

Theo Kingma, former Hollywood Foreign Press Association president, died March 21 in his Los Angeles home. He was 58. Kingma’s death was confirmed to Variety by Kingma’s publicist. While a ...